Keyphrases
Non-small Cell Lung Cancer (NSCLC)
72%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
56%
Immune Checkpoint Inhibitors
48%
Overall Survival
25%
Lung Cancer
22%
Nivolumab
19%
Confidence Interval
19%
Progression-free Survival
18%
Chemotherapy
16%
Osimertinib
14%
Non-small Cell Lung Cancer Patients
13%
Hazard Ratio
13%
Median Overall Survival
13%
Cancer Center
12%
ALK-positive Lung Cancer
12%
CNS Metastases
12%
Real-life Cohort
12%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
11%
Venous Thromboembolism
11%
Next-generation Sequencing
11%
Partial Response
10%
NSCLC Patients
10%
Objective Response Rate
10%
Adverse Events
9%
Platinum-based Chemotherapy
9%
Brain Metastases
9%
ROS1
9%
ALK Inhibitor
8%
Consecutive Patients
8%
Circulating Tumor DNA (ctDNA)
8%
Lung
8%
Crizotinib
8%
EGFR mutation
8%
Pembrolizumab
8%
Median Progression-free Survival
7%
Large Cell Neuroendocrine Tumor
7%
PD-L1 Tumor Proportion Score
7%
Response to Therapy
7%
Stereotactic Radiosurgery
7%
High-dose Radiotherapy
7%
Clinical Impact
7%
BRAF mutant
7%
Epidermal Growth Factor Receptor
7%
Mobocertinib
7%
EGFR Exon 20 Insertion
7%
Overall Response Rate
7%
Anaplastic Lymphoma Kinase
7%
Systemic Treatment
7%
Israel
7%
Stable Disease
7%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Immune Checkpoint Inhibitor
42%
Lung Cancer
35%
Overall Survival
31%
Neoplasm
24%
Progression Free Survival
23%
Epidermal Growth Factor Receptor
22%
Nivolumab
19%
Disease
18%
Non-Small Cell Lung Cancer
17%
Radiation Therapy
17%
Malignant Neoplasm
15%
Retrospective Study
13%
Osimertinib
12%
Brain Metastasis
12%
Tyrosine-Kinase Inhibitor
12%
Venous Thromboembolism
11%
Hazard Ratio
11%
Central Nervous System Metastasis
11%
Anaplastic Lymphoma Kinase
10%
Adverse Event
10%
Lung Adenocarcinoma
9%
Large Cell
8%
Programmed Death-Ligand 1
8%
Electrocorticography
8%
Arm
8%
Neuroendocrine Tumor
7%
Pleura Mesothelioma
7%
Biological Marker
7%
Circulating Tumor DNA
7%
Drug Megadose
7%
Crizotinib
7%
Systemic Therapy
7%
Small Cell Lung Cancer
6%
Next Generation Sequencing
6%
Central Nervous System
6%
Adenocarcinoma
6%
Epidermal Growth Factor Receptor Kinase Inhibitor
5%
Chemoradiotherapy
5%
Exon
5%
Lung Carcinoma
5%
Magnetic Resonance Imaging
5%
Targeted Therapy
5%
Immunotherapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
93%
Immune Checkpoint Inhibitor
37%
Lung Cancer
35%
Chemotherapy
34%
Overall Survival
34%
Epidermal Growth Factor Receptor
28%
Neoplasm
22%
Progression Free Survival
21%
Disease
20%
Protein Tyrosine Kinase Inhibitor
15%
Adverse Event
14%
Anaplastic Lymphoma Kinase
14%
Retrospective Study
13%
Osimertinib
12%
Nivolumab
11%
Venous Thromboembolism
11%
Crizotinib
10%
Malignant Neoplasm
9%
Brain Metastasis
9%
Systemic Treatment
8%
Pleura Mesothelioma
7%
Circulating Tumor DNA
7%
Pembrolizumab
7%
Ceritinib
7%
Lung Adenocarcinoma
6%
Chemoradiation Therapy
6%
Epidermal Growth Factor Receptor Kinase Inhibitor
6%
Adenocarcinoma
6%
Monotherapy
5%